Trial reportBlood2018
Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome.
Trial report in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 106 citations in OpenAlex.
- Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.Frontiers in immunology · 2022Pooled it
- A Chinese case series of Schnitzler syndrome and complete remission in one tocilizumab-treated patient.Clinical rheumatology · 2020Pooled it
- Schnitzler Syndrome as an Autoinflammatory Disease Driven by B-Cell-Specific Somatic MYD88 Mutation.Allergy · 2026Article
- Long-term anakinra therapy in Schnitzler syndrome: real-world evidence on remission of neutrophilic dermatitis and systemic inflammation, safety, biomarker insights and dose optimization.Frontiers in immunology · 2026Observational
- Schnitzler syndrome - a rare cause of chronic urticaria. Case report.Oxford medical case reports · 2025Article
- Schnitzler syndrome.Dermatologie (Heidelberg, Germany) · 2025Review
- Neutrophilic Urticarial Dermatosis: A Window into Systemic Inflammation and Autoimmune Disorders.Clinical reviews in allergy & immunology · 2025Review
- Characterization of Genetic Landscape and Novel Inflammatory Biomarkers in Patients With Adult-Onset Still's Disease.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- FACS-based detection of extracellular ASC specks from NLRP3 inflammasomes in inflammatory diseases.Clinical and experimental immunology · 2025Article
- Background and Clinical Features of a Unique and Mysterious Autoinflammatory Disease, Schnitzler Syndrome.International journal of molecular sciences · 2025Review
- Case report: Therapeutic use of bortezomib in a patient with Schnitzler syndrome.Frontiers in immunology · 2025Article
- Clinical and laboratory markers to distinguish VEXAS from Schnitzler's syndrome: data from the AIDA network registries.Frontiers in medicine · 2025Article
- Schnitzler's Syndrome-Diagnostic Experience, Approaches to Therapy, and Patient Management according to a Multicenter Russian Cohort.Doklady. Biochemistry and biophysics · 2024Observational
- Schnitzler Syndrome: Insights into Its Pathogenesis, Clinical Manifestations, and Current Management.Biomolecules · 2024Review
- Hypertonic saline induces inflammation in human macrophages through the NLRP1 inflammasome.Genes and immunity · 2023Article
- Prevalence of MGCS Among Patients With Monoclonal Gammopathies.HemaSphere · 2023Article
- Investigator-Determined Categories for Fever of Unknown Origin (FUO) Compared With International Classification of Diseases-10 Classification of Illness: A Systematic Review and Meta-analysis With a Proposal for Revised FUO Classification.Open forum infectious diseases · 2023Article
- Dermatologic Manifestations of Noninflammasome-Mediated Autoinflammatory Diseases.JID innovations : skin science from molecules to population health · 2023Review
- IgM monoclonal gammopathies of clinical significance: diagnosis and management.Haematologica · 2022Review
- Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin.Haematologica · 2022Article
Corrections and comments
- Commented on by
Authors and funding
19 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To date, the pathogenic mechanisms underlying Schnitzler syndrome remain obscure, in particular, the interplay between the monoclonal protein and increased interleukin-1β (IL-1β) production, although interest in the contribution of genetic factors has been fueled by detection of somatic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.